ThermoGenesis (THMO) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 09, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	333-82900
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3018487
Entity Address, Address Line One	2711 Citrus Road
Entity Address, City or Town	Rancho Cordova
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95742
City Area Code	916
Local Phone Number	858-5100
Title of 12(b) Security	Common Stock, $.001 par value
Trading Symbol	THMO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		3,136,504
Entity Central Index Key	0000811212
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,018,000	$ 4,177,000
Accounts receivable, net of allowance for credit losses of $2,000 ($149,000 at December 31, 2022)	368,000	1,865,000
Inventories	1,821,000	3,334,000
Prepaid expenses and other current assets	718,000	1,508,000
Total current assets	6,925,000	10,884,000
Inventories, non-current	772,000	1,003,000
Equipment and leasehold improvements, net	2,523,000	1,254,000
Right-of-use operating lease assets, net	190,000	372,000
Goodwill	781,000	781,000
Intangible assets, net	1,262,000	1,286,000
Other assets	255,000	256,000
Total assets	15,921,000	19,386,000
Accounts payable	591,000	820,000
Accrued payroll and related expenses	451,000	399,000
Deferred revenue – short-term	818,000	782,000
Convertible promissory note – related party	4,817,000	5,777,000
Interest payable – related party	225,000	1,492,000
Convertible promissory note, net	456,000	962,000
Other current liabilities	1,532,000	1,277,000
Total current liabilities	8,890,000	11,509,000
Operating lease obligations – long-term		131,000
Deferred revenue – long-term	680,000	911,000
Other noncurrent liabilities	17,000	17,000
Total liabilities	12,658,000	16,063,000
Commitments and Contingencies
Common stock, $0.001 par value; 350,000,000 shares authorized; 3,136,504 issued and outstanding (1,037,138 at December 31, 2022)	3,000	1,000
Additional paid in capital	281,632,000	270,377,000
Accumulated deficit	(277,154,000)	(266,193,000)
Accumulated other comprehensive loss	114,000	111,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	4,595,000	4,296,000
Noncontrolling interests	(1,332,000)	(973,000)
Total equity	3,263,000	3,323,000
Total liabilities and equity	15,921,000	19,386,000
Lease Agreement with Z3 Investment LLC [Member]
Current assets:
Right-of-use operating lease assets, net	3,213,000	3,550,000
Operating lease obligations – long-term	$ 3,071,000	$ 3,495,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accounts receivable, allowance for doubtful accounts	$ 2,000	$ 149,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common Stock, Shares, Outstanding (in shares)	3,136,504	1,037,138
Common Stock, Shares, Issued (in shares)	3,136,504	1,037,138

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net revenues	$ 2,194,000	$ 2,115,000	$ 7,039,000	$ 7,807,000
Cost of revenues	1,799,000	1,678,000	5,070,000	5,491,000
Gross profit	395,000	437,000	1,969,000	2,316,000
Selling, general and administrative	1,686,000	1,982,000	5,346,000	5,665,000
Research and development	266,000	470,000	955,000	1,317,000
Total operating expenses	1,952,000	2,452,000	6,301,000	6,982,000
Loss from operations	(1,557,000)	(2,015,000)	(4,332,000)	(4,666,000)
Other expenses:
Interest expense	(2,118,000)	(1,391,000)	(6,689,000)	(3,572,000)
Loss on retirement of debt	(87,000)		(326,000)
Other income (expenses)	(22,000)	(3,000)	(27,000)	1,000
Total other expenses	(2,183,000)	(1,388,000)	(6,988,000)	(3,573,000)
Net loss	(3,740,000)	(3,403,000)	(11,320,000)	(8,239,000)
Loss attributable to noncontrolling interests	(125,000)	(163,000)	(359,000)	(402,000)
Net loss attributable to common stockholders	(3,615,000)	(3,240,000)	(10,961,000)	(7,837,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Net loss	(3,740,000)	(3,403,000)	(11,320,000)	(8,239,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	9,000	22,000	3,000	67,000
Comprehensive loss	(3,731,000)	(3,381,000)	(11,317,000)	(8,172,000)
Comprehensive loss attributable to noncontrolling interests	(125,000)	(163,000)	(359,000)	(402,000)
Comprehensive loss attributable to common stockholders	$ (3,606,000)	$ (3,218,000)	$ (10,958,000)	$ (7,770,000)
Earnings Per Share [Abstract]
Basic and diluted net loss per common share (in dollars per share)	$ (1.44)	$ (4.66)	$ (5.26)	$ (18.49)
Weighted average common shares outstanding basicand diluted (in shares)	2,503,631	694,795	2,083,095	423,897

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	Common Stock [Member] At The Market Offering Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Additional Paid-in Capital [Member] Related Party Convertible Debt Price Reset [Member]	Additional Paid-in Capital [Member] At The Market Offering Agreement [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Noncontrolling Interest [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Related Party Convertible Debt Price Reset [Member]	At The Market Offering Agreement [Member]	Total
Balance (in shares) at Dec. 31, 2021		279,629
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021			$ (10,681,000)				$ 9,739,000					$ (942,000)
Balance at Dec. 31, 2021						$ 268,459,000		$ (264,662,000)	$ 31,000	[1]	$ (431,000)				$ 3,397,000
Stock-based compensation expense						42,000									42,000
Related party convertible note price reset				$ 213,000									$ 213,000
Sale of common stock and warrants, net (in shares)	20,407
Sale of common stock and warrants, net					$ 594,000									$ 594,000
Foreign currency translation gain									14,000	[1]					14,000
Net loss								(1,910,000)			(126,000)				(2,036,000)
Balance (in shares) at Mar. 31, 2022		300,036
Balance at Mar. 31, 2022						258,627,000		(256,833,000)	45,000	[1]	(557,000)				1,282,000
Balance (in shares) at Dec. 31, 2021		279,629
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021			$ (10,681,000)				$ 9,739,000					$ (942,000)
Balance at Dec. 31, 2021						268,459,000		(264,662,000)	31,000	[1]	(431,000)				3,397,000
Foreign currency translation gain															67,000
Balance (in shares) at Sep. 30, 2022		710,967
Balance at Sep. 30, 2022		$ 1,000				267,761,000		(262,761,000)	98,000	[1]	(833,000)				4,266,000
Balance (in shares) at Mar. 31, 2022		300,036
Balance at Mar. 31, 2022						258,627,000		(256,833,000)	45,000	[1]	(557,000)				1,282,000
Stock-based compensation expense						72,000									72,000
Related party convertible note price reset				2,475,000									2,475,000
Conversion of note payable to common stock (in shares)		234,495
Conversion of note payable to common stock		$ 1,000				2,999,000									3,000,000
Sale of common stock and warrants, net (in shares)	97,726
Sale of common stock and warrants, net					1,450,000									1,450,000
Foreign currency translation gain									31,000	[1]					31,000
Net loss								(2,688,000)			(113,000)				(2,801,000)
Conversion of related party note payable to common stock (in shares)		234,495
Conversion of related party note payable to common stock		$ 1,000				2,999,000									3,000,000
Balance (in shares) at Jun. 30, 2022		632,257
Balance at Jun. 30, 2022		$ 1,000				265,623,000		(259,521,000)	76,000	[1]	(670,000)				5,509,000
Stock-based compensation expense						70,000									70,000
Related party convertible note price reset				1,075,000									1,075,000
Sale of common stock and warrants, net (in shares)	78,710
Sale of common stock and warrants, net					$ 993,000									$ 993,000
Foreign currency translation gain									22,000	[1]					22,000
Net loss								(3,240,000)			(163,000)				(3,403,000)
Balance (in shares) at Sep. 30, 2022		710,967
Balance at Sep. 30, 2022		$ 1,000				267,761,000		(262,761,000)	98,000	[1]	(833,000)				4,266,000
Balance (in shares) at Dec. 31, 2022		1,037,138
Balance at Dec. 31, 2022		$ 1,000				270,377,000		(266,193,000)	111,000		(973,000)				3,323,000
Stock-based compensation expense						10,000									10,000
Related party convertible note price reset				3,160,000		43,000							3,160,000		43,000
Conversion of note payable to common stock (in shares)		215,000
Conversion of note payable to common stock		$ 1,000				602,000									603,000
Sale of common stock and warrants, net (in shares)		125,000
Sale of common stock and warrants, net						2,640,000									2,640,000
Exercise of warrants (in shares)		158,731
Exercise of warrants						421,000									421,000
Foreign currency translation gain									(6,000)						(6,000)
Net loss								(5,086,000)			(96,000)				(5,182,000)
Conversion of related party note payable to common stock (in shares)		215,000
Conversion of related party note payable to common stock		$ 1,000				602,000									603,000
Balance (in shares) at Mar. 31, 2023		1,535,869
Balance at Mar. 31, 2023		$ 2,000				277,253,000		(271,279,000)	105,000		(1,069,000)				5,012,000
Balance (in shares) at Dec. 31, 2022		1,037,138
Balance at Dec. 31, 2022		$ 1,000				270,377,000		(266,193,000)	111,000		(973,000)				3,323,000
Related party convertible note price reset													6,820,000
Sale of common stock and warrants, net (in shares)														196,843
Foreign currency translation gain															3,000
Balance (in shares) at Sep. 30, 2023		3,136,504
Balance at Sep. 30, 2023		$ 3,000				281,632,000		(277,154,000)	114,000		(1,332,000)				3,263,000
Balance (in shares) at Mar. 31, 2023		1,535,869
Balance at Mar. 31, 2023		$ 2,000				277,253,000		(271,279,000)	105,000		(1,069,000)				5,012,000
Stock-based compensation expense						13,000									13,000
Exercise of warrants (in shares)		946,429
Net loss								(2,260,000)			(138,000)				(2,398,000)
Balance (in shares) at Jun. 30, 2023		2,482,298
Balance at Jun. 30, 2023		$ 2,000				277,266,000		(273,539,000)	105,000		(1,207,000)				2,627,000
Stock-based compensation expense						7,000									7,000
Related party convertible note price reset				$ 3,660,000									$ 3,660,000
Conversion of note payable to common stock (in shares)		654,206
Conversion of note payable to common stock		$ 1,000				699,000									700,000
Foreign currency translation gain									9,000						9,000
Net loss								(3,615,000)			(125,000)				(3,740,000)
Conversion of related party note payable to common stock (in shares)		654,206
Conversion of related party note payable to common stock		$ 1,000				699,000									700,000
Balance (in shares) at Sep. 30, 2023		3,136,504
Balance at Sep. 30, 2023		$ 3,000				$ 281,632,000		$ (277,154,000)	$ 114,000		$ (1,332,000)				$ 3,263,000
[1]Accumulated other comprehensive loss.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss	$ (11,320,000)	$ (8,239,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	816,000	666,000
Stock based compensation expense	30,000	184,000
Amortization of debt discount/premium, net	5,396,000	1,897,000
Reserve for excess and slow-moving inventories	480,000	654,000
Loss on retirement of debt	326,000
Net change in operating assets and liabilities:
Accounts receivable	1,496,000	(1,323,000)
Inventories	1,264,000	582,000
Prepaid expenses and other assets	791,000	757,000
Accounts payable	(226,000)	(210,000)
Interest payable – related party	(289,000)	(1,132,000)
Accrued payroll and related expenses	52,000	145,000
Deferred revenue – short-term	37,000	122,000
Other current liabilities	255,000	446,000
Long-term deferred revenue and other noncurrent liabilities	(786,000)	(650,000)
Net cash used in operating activities	(1,678,000)	(6,101,000)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Capital expenditures	(1,541,000)	(308,000)
Net cash used in investing activities	(1,541,000)	(308,000)
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from issuance of common stock, net of expenses	2,640,000	3,037,000
Proceeds from the exercise of warrants	421,000
Net cash provided by financing activities	3,061,000	3,037,000
Effects of foreign currency rate changes on cash and cash equivalents	(1,000)	(5,000)
Net increase (decrease) in cash and cash equivalents	(159,000)	(3,377,000)
Cash and cash equivalents at beginning of period	4,177,000	7,280,000
Cash and cash equivalents at end of period	4,018,000	3,903,000
Supplemental Cash Flow Information [Abstract]
Cash paid for related party interest	1,492,000	2,628,000
Cash paid for interest	140,000	180,000
Right-to-use asset acquired under operating lease, related party		3,863,000
Related Party Convertible Debt Price Reset [Member]
Supplemental Cash Flow Information [Abstract]
Convertible note price reset	6,820,000
Nonrelated Party [Member]
Supplemental Cash Flow Information [Abstract]
Convertible note price reset	43,000
Related party convertible note converted to common stock	603,000
Related Party [Member]
Supplemental Cash Flow Information [Abstract]
Related party convertible note converted to common stock	700,000	$ 3,000,000
January 2023 Convertible Note [Member]
Supplemental Cash Flow Information [Abstract]
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note	1,239,000
July 2023 Convertible Note [Member]
Supplemental Cash Flow Information [Abstract]
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note	$ 484,000

Note 1 - Description of Busines

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business Overview ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”) develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. Since the 1990’s, ThermoGenesis Holdings has been a pioneer in, and a leading provider of automated systems that isolate, purify and cryogenically store units of hematopoietic stem and progenitor cells for the cord blood banking industry. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA. Our common stock is traded on the Nasdaq Capital Market under the ticker symbol “THMO”. Medical Device Products for Automated Cell Processing The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and the CAR-TXpress™ platform for large scale cell manufacturing services. All product lines are reporting as a single reporting segment in the financial statements. CDMO Business The Company is expanding its business to include contract development and manufacturing services for cell and cell-based gene therapies. The Company is in the process of building out the capabilities to become a world-class Contract Development and Manufacturing Organization (“CDMO”) for cell and cell-based gene therapies. The Company is building out a new facility in the Sacramento metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy companies. The ReadyStart Suites are located in a 35,500+ square foot cGMP facility that will meet the highest scientific, quality, and regulatory requirements. The CDMO facility was completed in October of 2023. Reverse Stock Split On December 22, 2022, we effected a one (1) for forty-five ( 45

Note 2 - Going Concern

Note 2 - Going Concern	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Going Concern The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future. The Company may need to raise additional capital to grow its business, fund operating expenses and make interest payments. The Company’s ability to fund its liquidity needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the Company, if at all. These factors and other indicators raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing date of this report. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Polices There have been no material changes in the Company’s significant accounting policies to those disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of the results for the periods presented have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three and nine months ended September 30, 2023, are not necessarily indicative of the results that may be expected for the Company’s fiscal year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings’ Annual Report on Form 10-K for the year ended December 31, 2022. Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio, Inc. (“CARTXpress Bio”). All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an 80% ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section. Recently Adopted Accounting Standards On January 1, 2022, we adopted Accounting Standards Update (“ASU”) 2020-06 “ Debt-Debt with Conversion and Other Options ( Subtopic 470-20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815-40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses ( Topic 326 ).

Note - 4 Related Party Transact

Note - 4 Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	4. Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Group (USA), Inc. (the “Lender”), which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to the maturity date. On March 6, 2023, the Company entered into an Amendment No. 2 (the “Amendment to the Note”) to its Second Amended and Restated Convertible Promissory Note with Boyalife Group Inc. (the “Note”), and an Amendment No. 3 to its First Amended and Restated Revolving Credit Agreement with Boyalife Group Inc. The Amendment to the Note amended and extended the maturity date of the Note from March 6, 2023 to December 31, 2023 (the “Maturity Date”) and added to the principal balance of the Note all accrued and unpaid interest at the time of the extension, resulting in an outstanding principal balance of $7,278,000 as of March 6, 2023. The Company performed a debt extinguishment vs. modification analysis on the Amendment to the Note and determined that the amendment would be considered an extinguishment, due to an increase of more than 10% to the value of the embedded conversion option. However, no gain or loss was recorded in the condensed consolidated statements of operations and comprehensive loss at the time of the Amendment as it was determined that the fair value of the Amendment to the Note and accrued interest was the same before and after the extension. On September 28, 2023, the Company received a conversion notice from the Lender to convert a total of $700,000 of the outstanding accrued interest. The conversion resulted in an issuance of 654,206 shares of the Company’s common stock at a conversion price of $1.07 per share. Immediately following the conversion, the outstanding principal balance of the Note was $7,278,000 and accrued but unpaid interest of $216,000. The Credit Agreement and the Note, as amended provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. The Loan can be prepaid in whole or in part by the Company at any time without penalty. The following summarizes the Note: Maturity Date Stated Interest Rate Conversion Price Face Value Debt Discount Carrying Value September 30, 2023 12/31/23 22 % $ 1.07 $ 7,278,000 $ (2,461,000 ) $ 4,817,000 December 31, 2022 12/31/23 22 % $ 6.30 $ 7,000,000 $ (1,223,000 ) $ 5,777,000 The Note includes a down-round anti-dilution provision that lowers its conversion price if the Company sells shares of common stock or issues convertible debt at a lower price per share. Through September 30, 2023, the down-round provision was triggered as noted below: In January 2023, when the conversion price of the Note was at $6.30 per share, the Company amended a previously outstanding convertible note, resulting in a triggering event lowering the conversion price of the Note to $2.87. The Company determined that it created an incremental value of $2,350,000 which was treated as a discount to the carrying amount of the Note and amortized over its remaining term. In March 2023, the Company sold shares of common stock and warrants at $2.65 per share, resulting in a down round triggering event lowering the conversion price of the Note to that value. The triggering event created an incremental value of $810,000 which was treated as a discount to the carrying amount of the Note and will be amortized over its remaining term. In July 2023, when the conversion price of the Note was at $2.65 per share, the Company amended a previously outstanding convertible note, resulting in a triggering event lowering the conversion price of the Note to $1.07. The Company determined that it created an incremental value of $3,660,000 which was treated as a discount to the carrying amount of the Note and amortized over its remaining term. A Black-Scholes pricing model was utilized to determine the change in the before and after incremental value of the conversion option at each triggering event, with the following inputs: January 2023 March 2023 July 2023 Conversion price before $ 6.30 $ 2.87 $ 2.65 Conversion price after $ 2.87 $ 2.65 $ 1.07 Term (years) 0.09 0.78 0.42 Volatility 167 % 168.9 % 156.8 % Dividend rate 0 % 0 % 0 % Risk free rate 4.46 % 4.20 % 4.22 % For the three and nine months ended September 30, 2023, the Company amortized $1,720,000 and $5,582,000 of debt discount related to triggering events, compared to $940,000 and $1,897,000 for the three and nine months ended September 30, 2022. In addition to the amortization, the Company also recorded interest expense of $409,000 and $1,203,000 for the three and nine months ended September 30, 2023, compared to $394,000 and $1,496,000 for the three and nine months ended September 30, 2022, respectively. The interest payable balance as of September 30, 2023 and December 31, 2022 was $225,000 and $1,492,000, respectively. Boyalife Genomics On March 24, 2022, the Company entered into a License and Technology Access Agreement with Boyalife Genomics Tianjin Ltd. (“Boyalife Genomics”), a China-based CDMO and an affiliate of ThermoGenesis’ Chairman and Chief Executive Officer, Chris Xu, Ph.D. The agreement provides for a U.S. license to certain existing and future know-how and other intellectual property relating to cell manufacturing and related processes. The Company plans to develop and operate the CDMO cell therapy manufacturing business through a division named TG Biosynthesis. Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte, Inc. to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one or more of Boyalife Genomics’ granted U.S. patents and a royalty of 5.0% of other products and services covered by other licensed intellectual property. In the three and nine months ended September 30, 2023, no sales were recorded under the license agreement and no royalty payments were made to Boyalife Genomics.

Note 5 - Related Party Lease

Note 5 - Related Party Lease	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	5. Related Party Lease Z3 Investment On March 24, 2022, the Company entered into a five-year Operating Lease Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we use the Company’s cost of capital based on existing debt instruments. We recognize the expense for this lease on a straight-line basis over the lease term. The following summarizes the Company’s operating lease: September 30, 2023 December 31, 2022 Right-of-use operating lease assets – related party, net $ 3,213,000 $ 3,550,000 Current lease liability (included in other current liabilities) 551,000 433,000 Non-current lease liability – related party 3,071,000 3,495,000 Weighted average remaining lease term 4.0 4.8 Discount rate 22 % 22 % Maturities of lease liabilities by year for our operating lease are as follows: 2023 (Remaining) $ 324,000 2024 1,307,000 2025 1,359,000 2026 1,428,000 Thereafter 1,133,000 Total lease payments $ 5,551,000 Less: imputed interest (1,930,000 ) Present value of operating lease liabilities $ 3,621,000 Statement of Cash Flows Cash paid for amounts included in the measurement of operating lease liabilities was $932,000 and $277,000 for the nine months ended September 30, 2023 and 2022, respectively.

Note 6 - Convertible Promissory

Note 6 - Convertible Promissory Note	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Convertible Promissory Note July 2019 Note On July 23, 2019, the Company entered into a private placement with Orbrex (USA) Co. Limited (“Orbrex”), pursuant to which the Company issued and sold to Orbrex an unsecured convertible promissory note, as amended, in the original principal amount of $1,000,000 (the “July 2019 Note”). The July 2019 Note bears interest at a rate of twenty-four percent (24%) per annum and is payable in arrears on January 31 of each year. In the nine months ended September 30, 2023, the Company has amended the July 2019 Note two times: ● On January 31, 2023, the Company entered into Amendment No. 3 to the July 2019 Note, which extended the maturity date from January 31, 2023 to July 31, 2023 and changed the fixed conversion price to $2.87 per share. The Company performed a debt extinguishment vs. modification analysis on this amendment to the July 2019 Note and determined that the extension would be considered an extinguishment, due to an increase of more than 10% to the value of the embedded conversion option. The Company determined that the fair value of the July 2019 Note after the amendment was $1,239,000 representing a $239,000 increase in its fair value. The increase will be recorded as a premium to the July 2019 Note and was amortized over the remaining term. ● On July 31, 2023, the Company entered into an Amendment No. 4 to the July 2019 Note, which extended the maturity date of the July 2019 Note from July 31, 2023 to January 31, 2024 and changed the fixed conversion price to $1.07 per share. The Company performed a debt extinguishment vs. modification analysis on this amendment to the July 2019 Note and determined that the extension would be considered an extinguishment, due to an increase of more than 10% to the value of the embedded conversion option. The Company determined that the fair value of the July 2019 Note after the amendment was $538,000 representing a $87,000 increase in its fair value. The increase will be recorded as a premium to the July 2019 Note and amortized over the remaining term. The following summarizes the July 2019 Note: Maturity Date Stated Interest Rate Conversion Price Face Debt Carrying Value September 30, 2023 1/31/2024 24% $ 1.07 $ 397,000 $ 59,000 $ 456,000 December 31, 2022 7/31/2023 24% $ 6.30 $ 1,000,000 $ (38,000 ) $ 962,000 The July 2019 Note includes a down-round anti-dilution provision that lowers its conversion price if the Company sells shares of common stock or issues convertible debt at a lower price per share. In 2023, the anti-dilution provision was triggered, as noted below: In March 2023, the Company sold shares of common stock at $2.65 per share, resulting in a down round triggering event lowering the conversion price of the Note to that value. The triggering event created an incremental value of $43,000 which was treated as a discount to the carrying amount of the July 2019 Note and was be amortized over its remaining term. A Black-Scholes pricing model was utilized to determine the change in the before and after incremental value of the conversion option at each triggering event, with the following inputs: March 2023 Conversion price before $ 2.87 Conversion price after $ 2.65 Term (years) 0.36 Volatility 182 % Dividend rate 0 % Risk free rate 4.20 % The Company recorded amortization expense for the July 2019 Note of ($35,000) and ($186,000)

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	7. Stockholders Equity Common Stock On March 15, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to issue and sell to the Investor in a private placement (the “Offering”) (i) 125,000 shares of its common stock, $0.001 par value (the “Common Shares”), (ii) 946,429 pre-funded warrants to purchase Common Shares at a purchase price of $2.80, and (iii) common stock warrants to purchase up to an aggregate 1,071,429 Common Shares were issued (the “Underlying Shares”). The common stock warrants have an exercise price of $2.65 per share and are exercisable immediately upon issuance and expire five In connection with the Offering, the Company entered into a Warrant Amendment Agreement (the "Warrant Amendment Agreement”), dated March 15, 2023, with the Investor, whereby the Company agreed to amend existing warrants, held by the Investor, to purchase up to an aggregate of 158,731 shares of common stock that were previously issued in October 2022. These warrants had an exercise price of $6.30 per share and pursuant to the Warrant Amendment Agreement have been amended to reduce the exercise price to $2.65 per share effective upon the closing of the Offering. During the nine months ended September 30, 2023, 158,731 common warrants were exercised. The Company received approximately $421,000 from the exercises of the warrants. The warrant repricing resulted in an immediate and incremental increase of approximately $50,000 in the estimated fair value of the common warrants issued in the Company’s October 2022 public offering. The common warrants were valued on the date of the warrant repricing using the Black-Scholes option pricing model based on the following assumptions: March 2023 Conversion price before $ 6.30 Conversion price after $ 2.65 Term (years) 4.9 Volatility 123 % Dividend rate 0 % Risk free rate 4.20 % On February 3, 2022, the Company entered into Amendment No. 2 to the At the Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC to further increase the maximum aggregate offering price of shares of Common Stock that may be offered and sold from time to time under the Offering Agreement from $15,280,000 to $19,555,000, which enables the Company to sell an additional $4,275,000 of shares after taking into account prior sales under the Offering Agreement (the “Additional Shares”). In March 2022, the total offering price was updated to $18,573,000 based on the shares that were currently available on Company’s existing Form S-3. The terms and conditions of the Offering Agreement otherwise remain unchanged. For the nine months ended September 30, 2022, the Company sold a total of 196,843 shares of common stock under the Offering Agreement for aggregate gross proceeds of $3,293,000 at an average selling price of $16.55 per share, resulting in net proceeds of approximately $3,037,000 after deducting commissions and other transaction costs of approximately $256,000. Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no vesting or other contingencies associated with them. All pre-funded warrants previously issued have been exercised and none are outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at September 30: 2023 2022 Common stock equivalents of convertible promissory notes and accrued interest 7,448,487 969,173 Warrants 1,238,869 14,518 Stock options 6,218 6,380 Total 8,693,574 990,071 Warrants A summary of warrant activity for the nine months ended September 30, 2023 is as follows: Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2022 340,689 $ 19.40 1.90 Warrants granted 1,071,429 Warrants expired (14,518 ) Pre-funded warrants granted 946,429 Pre-funded warrants exercised (946,429 ) Warrants exercised (158,731 ) Exercisable and Outstanding at September 30, 2023 1,238,869 $ 3.14 4.82

Note 8 - Revenue

Note 8 - Revenue	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	8. Revenue The following table presents net sales by geographic areas: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 United States $ 1,500,000 $ 1,535,000 $ 4,589,000 $ 4,973,000 China 29,000 364,000 77,000 1,570,000 United Arab Emirates 259,000 -- 439,000 -- Other 406,000 216,000 1,934,000 1,264,000 Total $ 2,194,000 $ 2,115,000 $ 7,039,000 $ 7,807,000 The following tables summarize the revenues by product line and type: Three Months Ended September 30, 2023 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,486,000 $ 88,000 $ -- $ 1,574,000 BioArchive 131,000 322,000 -- 453,000 CAR-TXpress 42,000 34,000 71,000 147,000 Manual Disposables 8,000 -- -- 8,000 Other 6,000 -- 6,000 12,000 Total $ 1,673,000 $ 444,000 $ 77,000 $ 2,194,000 Nine Months Ended September 30, 2023 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,245,000 $ 184,000 $ -- $ 4,429,000 BioArchive 879,000 1,020,000 -- 1,899,000 CAR-TXpress 101,000 109,000 213,000 423,000 Manual Disposables 229,000 -- -- 229,000 Other 41,000 -- 18,000 59,000 Total $ 5,495,000 $ 1,313,000 $ 231,000 $ 7,039,000 Three Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,034,000 $ 75,000 $ -- $ 1,109,000 BioArchive 201,000 321,000 -- 522,000 CAR-TXpress 190,000 44,000 72,000 306,000 Manual Disposables 150,000 -- -- 150,000 Other 20,000 -- 8,000 28,000 Total $ 1,595,000 $ 440,000 $ 80,000 $ 2,115,000 Nine Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,668,000 $ 171,000 $ -- $ 4,839,000 BioArchive 694,000 924,000 -- 1,618,000 CAR-TXpress 551,000 146,000 214,000 911,000 Manual Disposables 357,000 -- -- 357,000 Other 59,000 -- 23,000 82,000 Total $ 6,329,000 $ 1,241,000 $ 237,000 $ 7,807,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues that were included in the beginning balance of deferred revenue during the three and nine months ended September 30, 2023 were $144,000 and $663,000, respectively. Short-term deferred revenues were $818,000 and $782,000 at September 30, 2023 and December 31, 2022, respectively. Long-term deferred revenues were $680,000 and $911,000 at September 30, 2023 and December 31, 2022, respectively. Backlog of Remaining Customer Performance Obligations The following table represents revenue expected to be recognized in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period: Remainder of 2023 2024 2025 2026 2027 and beyond Total Service revenue $ 319,000 $ 741,000 $ 252,000 $ -- $ -- $ 1,312,000 Device revenue (1) 21,000 692,000 -- -- -- 713,000 Exclusivity fee 71,000 286,000 286,000 190,000 -- 833,000 Other 3,000 13,000 13,000 13,000 97,000 139,000 Total $ 414,000 $ 1,732,000 $ 551,000 $ 203,000 $ 97,000 $ 2,997,000 (1) Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 9 - Concentrations

Note 9 - Concentrations	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	9. Concentrations The Company had certain customers whose individual revenue was material to the Company’s total revenue, or whose accounts receivable balances were material to the Company’s total accounts receivable balances. Those customers are listed as follows: Accounts Receivable September 30, 2023 December 31, 2022 Customer 1 -- 29% Customer 2 -- 27% Customer 3 -- 15% Revenues Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Customer 1 41% 36% 36% 36% Customer 2 1% 1% 1% 13%

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of the results for the periods presented have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three and nine months ended September 30, 2023, are not necessarily indicative of the results that may be expected for the Company’s fiscal year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings’ Annual Report on Form 10-K for the year ended December 31, 2022.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio, Inc. (“CARTXpress Bio”). All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an 80% ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards On January 1, 2022, we adopted Accounting Standards Update (“ASU”) 2020-06 “ Debt-Debt with Conversion and Other Options ( Subtopic 470-20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815-40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses ( Topic 326 ).

Note - 4 Related Party Transa_2

Note - 4 Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Face Value Debt Discount Carrying Value September 30, 2023 12/31/23 22 % $ 1.07 $ 7,278,000 $ (2,461,000 ) $ 4,817,000 December 31, 2022 12/31/23 22 % $ 6.30 $ 7,000,000 $ (1,223,000 ) $ 5,777,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	January 2023 March 2023 July 2023 Conversion price before $ 6.30 $ 2.87 $ 2.65 Conversion price after $ 2.87 $ 2.65 $ 1.07 Term (years) 0.09 0.78 0.42 Volatility 167 % 168.9 % 156.8 % Dividend rate 0 % 0 % 0 % Risk free rate 4.46 % 4.20 % 4.22 %

Note 5 - Related Party Lease (T

Note 5 - Related Party Lease (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Lease, Cost [Table Text Block]	September 30, 2023 December 31, 2022 Right-of-use operating lease assets – related party, net $ 3,213,000 $ 3,550,000 Current lease liability (included in other current liabilities) 551,000 433,000 Non-current lease liability – related party 3,071,000 3,495,000 Weighted average remaining lease term 4.0 4.8 Discount rate 22 % 22 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2023 (Remaining) $ 324,000 2024 1,307,000 2025 1,359,000 2026 1,428,000 Thereafter 1,133,000 Total lease payments $ 5,551,000 Less: imputed interest (1,930,000 ) Present value of operating lease liabilities $ 3,621,000

Note 6 - Convertible Promisso_2

Note 6 - Convertible Promissory Note (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Convertible Debt [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Face Debt Carrying Value September 30, 2023 1/31/2024 24% $ 1.07 $ 397,000 $ 59,000 $ 456,000 December 31, 2022 7/31/2023 24% $ 6.30 $ 1,000,000 $ (38,000 ) $ 962,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	January 2023 March 2023 July 2023 Conversion price before $ 6.30 $ 2.87 $ 2.65 Conversion price after $ 2.87 $ 2.65 $ 1.07 Term (years) 0.09 0.78 0.42 Volatility 167 % 168.9 % 156.8 % Dividend rate 0 % 0 % 0 % Risk free rate 4.46 % 4.20 % 4.22 %
Convertible Debt [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	March 2023 Conversion price before $ 2.87 Conversion price after $ 2.65 Term (years) 0.36 Volatility 182 % Dividend rate 0 % Risk free rate 4.20 %

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	January 2023 March 2023 July 2023 Conversion price before $ 6.30 $ 2.87 $ 2.65 Conversion price after $ 2.87 $ 2.65 $ 1.07 Term (years) 0.09 0.78 0.42 Volatility 167 % 168.9 % 156.8 % Dividend rate 0 % 0 % 0 % Risk free rate 4.46 % 4.20 % 4.22 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2023 2022 Common stock equivalents of convertible promissory notes and accrued interest 7,448,487 969,173 Warrants 1,238,869 14,518 Stock options 6,218 6,380 Total 8,693,574 990,071
Schedule of Warrant Activity [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2022 340,689 $ 19.40 1.90 Warrants granted 1,071,429 Warrants expired (14,518 ) Pre-funded warrants granted 946,429 Pre-funded warrants exercised (946,429 ) Warrants exercised (158,731 ) Exercisable and Outstanding at September 30, 2023 1,238,869 $ 3.14 4.82
Warrants [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	March 2023 Conversion price before $ 6.30 Conversion price after $ 2.65 Term (years) 4.9 Volatility 123 % Dividend rate 0 % Risk free rate 4.20 %

Note 8 - Revenue (Tables)

Note 8 - Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 United States $ 1,500,000 $ 1,535,000 $ 4,589,000 $ 4,973,000 China 29,000 364,000 77,000 1,570,000 United Arab Emirates 259,000 -- 439,000 -- Other 406,000 216,000 1,934,000 1,264,000 Total $ 2,194,000 $ 2,115,000 $ 7,039,000 $ 7,807,000 Three Months Ended September 30, 2023 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,486,000 $ 88,000 $ -- $ 1,574,000 BioArchive 131,000 322,000 -- 453,000 CAR-TXpress 42,000 34,000 71,000 147,000 Manual Disposables 8,000 -- -- 8,000 Other 6,000 -- 6,000 12,000 Total $ 1,673,000 $ 444,000 $ 77,000 $ 2,194,000 Nine Months Ended September 30, 2023 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,245,000 $ 184,000 $ -- $ 4,429,000 BioArchive 879,000 1,020,000 -- 1,899,000 CAR-TXpress 101,000 109,000 213,000 423,000 Manual Disposables 229,000 -- -- 229,000 Other 41,000 -- 18,000 59,000 Total $ 5,495,000 $ 1,313,000 $ 231,000 $ 7,039,000 Three Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,034,000 $ 75,000 $ -- $ 1,109,000 BioArchive 201,000 321,000 -- 522,000 CAR-TXpress 190,000 44,000 72,000 306,000 Manual Disposables 150,000 -- -- 150,000 Other 20,000 -- 8,000 28,000 Total $ 1,595,000 $ 440,000 $ 80,000 $ 2,115,000 Nine Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,668,000 $ 171,000 $ -- $ 4,839,000 BioArchive 694,000 924,000 -- 1,618,000 CAR-TXpress 551,000 146,000 214,000 911,000 Manual Disposables 357,000 -- -- 357,000 Other 59,000 -- 23,000 82,000 Total $ 6,329,000 $ 1,241,000 $ 237,000 $ 7,807,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2023 2024 2025 2026 2027 and beyond Total Service revenue $ 319,000 $ 741,000 $ 252,000 $ -- $ -- $ 1,312,000 Device revenue (1) 21,000 692,000 -- -- -- 713,000 Exclusivity fee 71,000 286,000 286,000 190,000 -- 833,000 Other 3,000 13,000 13,000 13,000 97,000 139,000 Total $ 414,000 $ 1,732,000 $ 551,000 $ 203,000 $ 97,000 $ 2,997,000

Note 9 - Concentrations (Tables

Note 9 - Concentrations (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	September 30, 2023 December 31, 2022 Customer 1 -- 29% Customer 2 -- 27% Customer 3 -- 15% Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Customer 1 41% 36% 36% 36% Customer 2 1% 1% 1% 13%

Note 1 - Description of Busin_2

Note 1 - Description of Business (Details Textual)	Dec. 22, 2022
Stockholders' Equity Note, Stock Split, Conversion Ratio	45

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,263,000	$ 2,627,000	$ 5,012,000	$ 3,323,000	$ 4,266,000	$ 5,509,000	$ 1,282,000		$ 3,397,000
Retained Earnings [Member]
Equity, Including Portion Attributable to Noncontrolling Interest	(277,154,000)	(273,539,000)	(271,279,000)	(266,193,000)	(262,761,000)	(259,521,000)	(256,833,000)		(264,662,000)
Additional Paid-in Capital [Member]
Equity, Including Portion Attributable to Noncontrolling Interest	$ 281,632,000	$ 277,266,000	$ 277,253,000	$ 270,377,000	$ 267,761,000	$ 265,623,000	$ 258,627,000		268,459,000
Accounting Standards Update 2020-06 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Equity, Including Portion Attributable to Noncontrolling Interest									(942,000)
Accounting Standards Update 2020-06 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount								$ (942,000)
Accounting Standards Update 2020-06 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Retained Earnings [Member]
Equity, Including Portion Attributable to Noncontrolling Interest								9,739,000	9,739,000
Accounting Standards Update 2020-06 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Additional Paid-in Capital [Member]
Equity, Including Portion Attributable to Noncontrolling Interest								$ (10,681,000)	$ (10,681,000)
CAR-TXpress [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner	20%
Subsidiary, Ownership Percentage, Parent	80%

Note - 4 Related Party Transa_3

Note - 4 Related Party Transactions (Details Textual) - USD ($)			3 Months Ended		9 Months Ended
	Sep. 28, 2023	Mar. 24, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jul. 31, 2023	Mar. 31, 2023	Mar. 06, 2023	Jan. 31, 2023	Dec. 31, 2022	Mar. 31, 2017
Amortization of Debt Discount (Premium)					$ 5,396,000	$ 1,897,000
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 140,000	180,000
ImmuneCyte [Member]
Percent of Ownership Interest Transferred		8.64%
Royalty, Percent of Annual Net Sales, US Patents		7.50%
Royalty, Percent of Annual Net Sales, Other Licensed Intellectual Property		5%
Revolving Credit Facility [Member] | Boyalife Asset Holding II [Member]
Line of Credit Facility, Maximum Borrowing Capacity												$ 10,000,000
Long-Term Line of Credit	$ 7,278,000								$ 7,278,000
Debt Conversion, Original Debt, Amount	$ 700,000
Debt Conversion, Converted Instrument, Shares Issued	654,206
Debt Instrument, Convertible, Conversion Price	$ 1.07		$ 1.07		$ 1.07		$ 1.07	$ 2.65		$ 6.30	$ 6.30
Interest Payable	$ 216,000		$ 225,000		$ 225,000						$ 1,492,000
Debt Instrument, Interest Rate, Stated Percentage			22%		22%						22%
Share Price (in dollars per share)								$ 2.65		$ 2.87
Debt Instrument, Unamortized Discount			$ 2,461,000		$ 2,461,000					$ 2,350,000	$ 1,223,000
Amortization of Debt Discount (Premium)			1,720,000	$ 940,000	5,582,000	1,897,000
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 409,000	$ 394,000	$ 1,203,000	$ 1,496,000
Revolving Credit Facility [Member] | Boyalife Asset Holding II [Member] | Incremental Value Increase [Member]
Debt Instrument, Unamortized Discount							$ 3,660,000	$ 810,000

Note 4 - Related Party Transact

Note 4 - Related Party Transactions - Schedule of Related Party Transactions (Details) - Revolving Credit Facility [Member] - Boyalife Asset Holding II [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Sep. 28, 2023	Jul. 31, 2023	Mar. 31, 2023	Jan. 31, 2023
Debt Instrument, Maturity Date	Dec. 31, 2023	Dec. 31, 2023
Stated interest rate	22%	22%
Conversion price (in dollars per share)	$ 1.07	$ 6.30	$ 1.07	$ 1.07	$ 2.65	$ 6.30
Face value	$ 7,278,000	$ 7,000,000
Debt discount	(2,461,000)	(1,223,000)				$ (2,350,000)
Carrying value	$ 4,817,000	$ 5,777,000

Note 4 - Related Party Transa_2

Note 4 - Related Party Transactions - Fair Value Inputs (Details)	Jul. 01, 2023	Mar. 31, 2023	Jan. 01, 2023
Measurement Input, Conversion Price Before [Member]
Conversion price before	2.65	2.87	6.30
Measurement Input, Conversion Price [Member]
Conversion price before	1.07	2.65	2.87
Measurement Input, Expected Term [Member]
Conversion price before	0.42	0.78	0.09
Measurement Input, Price Volatility [Member]
Conversion price before	1.568	1.689	1.67
Measurement Input, Expected Dividend Rate [Member]
Conversion price before	0	0	0
Measurement Input, Risk Free Interest Rate [Member]
Conversion price before	0.0422	0.0420	0.0446

Note 5 - Related Party Lease (D

Note 5 - Related Party Lease (Details Textual) - Lease Agreement with Z3 Investment LLC [Member]		9 Months Ended
	Mar. 24, 2022 USD ($) ft²	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Lessee, Operating Lease, Term of Contract	5 years
Area of Real Estate Property | ft²	35,000
Second Six Months, Rental Expense, Operating Lease	$ 104,000
Percent Increase, Annual Rental Expense	4%
Operating lease, Operating Expenses, Per Month	$ 10,000
Operating Lease, Payments		$ 932,000	$ 277,000

Note 5 - Related Party Lease -

Note 5 - Related Party Lease - Lease Cost (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Right-of-use operating lease assets, net	$ 190,000	$ 372,000
Operating lease obligations – long-term		131,000
Lease Agreement with Z3 Investment LLC [Member]
Right-of-use operating lease assets, net	3,213,000	3,550,000
Current lease liability (included in other current liabilities)	551,000	433,000
Operating lease obligations – long-term	$ 3,071,000	$ 3,495,000
Weighted average remaining lease term (Year)	4 years	4 years 9 months 18 days
Discount rate	22%	22%

Note 5 - Related Party Lease _2

Note 5 - Related Party Lease - Lease Liability Maturity (Details)	Sep. 30, 2023 USD ($)
2023 (Remaining)	$ 324,000
2024	1,307,000
2025	1,359,000
2026	1,428,000
Thereafter	1,133,000
Total lease payments	5,551,000
Less: imputed interest	(1,930,000)
Present value of operating lease liabilities	$ 3,621,000

Note 6 - Convertible Promisso_3

Note 6 - Convertible Promissory Note (Details Textual) - USD ($)			3 Months Ended		9 Months Ended
	Jul. 31, 2023	Jan. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023	Dec. 31, 2022	Jul. 23, 2019
Amortization of Debt Discount (Premium)					$ 5,396,000	$ 1,897,000
The July 2019 Note [Member] | Convertible Debt [Member]
Debt Instrument, Face Amount			$ 397,000		$ 397,000			$ 1,000,000	$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage			24%		24%			24%	24%
Debt Instrument, Convertible, Conversion Price	$ 1.07	$ 2.87	$ 1.07		$ 1.07		$ 2.65	$ 6.30
Long-Term Debt, Fair Value	$ 538,000	$ 1,239,000
Liabilities, Fair Value Adjustment	$ 87,000	$ 239,000
Debt Instrument, Unamortized Discount							$ 43,000
Interest Expense, Debt			$ 24,000	$ 60,000	$ 90,000	$ 180,000
Antidilutive Triggering Event [Member] | Convertible Debt [Member]
Amortization of Debt Discount (Premium)			$ 35,000		$ 190,000

Note 6 - Convertible Promisso_4

Note 6 - Convertible Promissory Note- Schedule of Convertible Debt (Details) - The July 2019 Note [Member] - Convertible Debt [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Jul. 31, 2023	Mar. 31, 2023	Jan. 31, 2023	Jul. 23, 2019
Debt Instrument, Maturity Date	Jan. 31, 2024	Jul. 31, 2023
Stated interest rate	24%	24%				24%
Conversion price (in dollars per share)	$ 1.07	$ 6.30	$ 1.07	$ 2.65	$ 2.87
Face value	$ 397,000	$ 1,000,000				$ 1,000,000
Debt Instrument, Unamortized Discount (Premium), Net	59,000	(38,000)
Carrying value	$ 456,000	$ 962,000

Note 6 - Convertible Promisso_5

Note 6 - Convertible Promissory Note - Fair Value Inputs (Details)	Sep. 30, 2023	Jul. 01, 2023	Mar. 31, 2023	Jan. 01, 2023
Measurement Input, Conversion Price Before [Member]
Conversion price before		2.65	2.87	6.30
Measurement Input, Conversion Price [Member]
Conversion price before		1.07	2.65	2.87
Measurement Input, Expected Term [Member]
Conversion price before		0.42	0.78	0.09
Measurement Input, Price Volatility [Member]
Conversion price before		1.568	1.689	1.67
Measurement Input, Expected Dividend Rate [Member]
Conversion price before		0	0	0
Measurement Input, Risk Free Interest Rate [Member]
Conversion price before		0.0422	0.0420	0.0446
Convertible Debt [Member] | Measurement Input, Conversion Price Before [Member]
Conversion price before	2.87
Convertible Debt [Member] | Measurement Input, Conversion Price [Member]
Conversion price before	2.65
Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Conversion price before	0.36
Convertible Debt [Member] | Measurement Input, Price Volatility [Member]
Conversion price before	1.82
Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member]
Conversion price before	0
Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Conversion price before	0.0420

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)		3 Months Ended	9 Months Ended
	Mar. 15, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2022	Feb. 03, 2022
Stock Issued During Period, Shares, New Issues	125,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001	$ 0.001		$ 0.001
Class of Warrant or Right, Outstanding		1,238,869	1,238,869		340,689
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.14	$ 3.14		$ 19.40
Warrants and Rights Outstanding, Term		4 years 9 months 25 days	4 years 9 months 25 days		1 year 10 months 24 days
Proceeds from Issuance or Sale of Equity	$ 2,640,000,000,000
Payments of Stock Issuance Costs	$ 360,000,000
Warrants Exercised			158,731
Proceeds from Warrant Exercises			$ 421,000
Proceeds from Issuance of Common Stock, Net			$ 2,640,000	$ 3,037,000
Warrant Amendment Agreement [Member]
Stock Issued During Period, Shares, New Issues	158,731
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.30	$ 2.65	$ 2.65
Warrants Exercised			158,731
Proceeds from Warrant Exercises			$ 421,000
At The Market Offering Agreement [Member]
Stock Issued During Period, Shares, New Issues			196,843
Payments of Stock Issuance Costs			$ 256,000
Maximum Offering Price for Issuance of Common Stock						$ 18,573,000
Additional Common Stock, Shares Authorized							$ 4,275,000
Proceeds from Issuance of Common Stock			$ 3,293,000
Shares Issued, Average Price Per Share			$ 16.55
Proceeds from Issuance of Common Stock, Net			$ 3,037,000
At The Market Offering Agreement [Member] | Minimum [Member]
Maximum Offering Price for Issuance of Common Stock							15,280,000
At The Market Offering Agreement [Member] | Maximum [Member]
Maximum Offering Price for Issuance of Common Stock							$ 19,555,000
Pre-funded Warrant [Member]
Class of Warrant or Right, Outstanding	946,429
Share Price (in dollars per share)	$ 2.80
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,071,429
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.65
Warrants and Rights Outstanding, Term	5 years 6 months
Warrants Exercised		946,429	946,429
Warrants Issued in Connection with Underwritten Public Offering [Member]
Fair Value Adjustment of Warrants			$ 50,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Fair Value Valuation (Details)	Sep. 30, 2023
Measurement Input, Conversion Price Before [Member]
Conversion price before	6.30
Measurement Input, Conversion Price [Member]
Conversion price before	2.65
Measurement Input, Expected Term [Member]
Conversion price before	4.9
Measurement Input, Price Volatility [Member]
Conversion price before	1.23
Measurement Input, Expected Dividend Rate [Member]
Conversion price before	0
Measurement Input, Risk Free Interest Rate [Member]
Conversion price before	0.0420

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive securities (in shares)	8,693,574	990,071
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	7,448,487	969,173
Warrant [Member]
Antidilutive securities (in shares)	1,238,869	14,518
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	6,218	6,380

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Warrant Activity (Details) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Mar. 15, 2023	Dec. 31, 2022
Balance, shares (in shares)		340,689
Balance, exercise price (in dollars per share)		$ 19.40
Balance, term (Year)	4 years 9 months 25 days	4 years 9 months 25 days		1 year 10 months 24 days
Warrants granted, shares (in shares)		1,071,429
Warrants expired (in shares)		(14,518)
Warrants exercised (in shares)		(158,731)
Exercisable, shares (in shares)	1,238,869	1,238,869
Balance, exercise price (in dollars per share)	$ 3.14	$ 3.14
Pre-funded Warrant [Member]
Balance, term (Year)			5 years 6 months
Warrants granted, shares (in shares)		946,429
Warrants exercised (in shares)	(946,429)	(946,429)

Note 8 - Revenue 1 (Details Tex

Note 8 - Revenue 1 (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Contract with Customer, Liability, Revenue Recognized	$ 144,000	$ 663,000
Contract with Customer, Liability, Current	818,000	818,000	$ 782,000
Contract with Customer, Liability, Noncurrent	$ 680,000	$ 680,000	$ 911,000

Note 8 - Revenue 2 (Details Tex

Note 8 - Revenue 2 (Details Textual)	Sep. 30, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	6 months
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	6 months
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	6 months
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	6 months
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year

Note 8 - Revenue - Disaggregati

Note 8 - Revenue - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net revenues	$ 2,194,000	$ 2,115,000	$ 7,039,000	$ 7,807,000
Device [Member] | AXP [Member]
Net revenues	1,574,000	1,109,000	4,429,000	4,839,000
Device [Member] | BioArchive [Member]
Net revenues	453,000	522,000	1,899,000	1,618,000
Device [Member] | CAR-TXpress [Member]
Net revenues	147,000	306,000	423,000	911,000
Device [Member] | Manual Disposables [Member]
Net revenues	8,000	150,000	229,000	357,000
Device [Member] | Other Subsegments [Member]
Net revenues	12,000	28,000	59,000	82,000
Device Revenue [Member]
Net revenues	1,673,000	1,595,000	5,495,000	6,329,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	1,486,000	1,034,000	4,245,000	4,668,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	131,000	201,000	879,000	694,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	42,000	190,000	101,000	551,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	8,000	150,000	229,000	357,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	6,000	20,000	41,000	59,000
Service [Member]
Net revenues	444,000	440,000	1,313,000	1,241,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	88,000	75,000	184,000	171,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	322,000	321,000	1,020,000	924,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	34,000	44,000	109,000	146,000
Other [Member]
Net revenues	77,000	80,000	231,000	237,000
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	71,000	72,000	213,000	214,000
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	6,000	8,000	18,000	23,000
UNITED STATES
Net revenues	1,500,000	1,535,000	4,589,000	4,973,000
CHINA
Net revenues	29,000	364,000	77,000	1,570,000
UNITED ARAB EMIRATES
Net revenues	259,000		439,000
All Other Countries [Member]
Net revenues	$ 406,000	$ 216,000	$ 1,934,000	$ 1,264,000

Note 8 - Revenue - Remaining Pe

Note 8 - Revenue - Remaining Performance Obligations (Details)	Sep. 30, 2023 USD ($)
Remaining	$ 2,997,000
Service [Member]
Remaining	1,312,000
Device Revenue [Member]
Remaining	713,000	[1]
Exclusivity Fee [Member]
Remaining	833,000
Other [Member]
Remaining	$ 139,000
[1]Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 8 - Revenue - Remaining _2

Note 8 - Revenue - Remaining Performance Obligations 2 (Details)	Sep. 30, 2023 USD ($)
Remaining	$ 2,997,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Remaining	414,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Remaining	1,732,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Remaining	551,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Remaining	203,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Remaining	97,000
Service [Member]
Remaining	1,312,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Remaining	319,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Remaining	741,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Remaining	252,000
Device Revenue [Member]
Remaining	713,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Remaining	21,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Remaining	692,000	[1]
Exclusivity Fee [Member]
Remaining	833,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Remaining	71,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Remaining	286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Remaining	286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Remaining	190,000
Other [Member]
Remaining	139,000
Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Remaining	3,000
Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Remaining	13,000
Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Remaining	13,000
Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Remaining	13,000
Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Remaining	$ 97,000
[1]Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 9 - Concentrations - Accou

Note 9 - Concentrations - Accounts Receivables and Revenues 2 (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from Contract with Customer Benchmark [Member] | Customer 1 [Member]
Concentration	41%	36%	36%	36%
Revenue from Contract with Customer Benchmark [Member] | Customer 2 [Member]
Concentration	1%	1%	1%	13%
Accounts Receivable [Member] | Customer 1 [Member]
Concentration				29%
Accounts Receivable [Member] | Customer 2 [Member]
Concentration				27%
Accounts Receivable [Member] | Customer 3 [Member]
Concentration				15%